<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547923</url>
  </required_header>
  <id_info>
    <org_study_id>CPP-380</org_study_id>
    <secondary_id>2008-000026-39</secondary_id>
    <nct_id>NCT01547923</nct_id>
  </id_info>
  <brief_title>Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines</brief_title>
  <acronym>DPD c√¥lon</acronym>
  <official_title>The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate the medical and financial benefit of pre-therapeutic
      screening of DPD deficiency for predicting toxicity to fluoropyrimidines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fluoropyrimidines, of which 5-Fluorouracil is the most important, represent a family of
      medication that is used in particular in cancerology. They are molecules widely used in
      cancerology since they can be found in nearly 45% of chemotherapy protocols and in the
      treatment of about 50% of cancers (colorectum, oesophagus, stomach, breast, upper digestive
      and respiratory tracts). They are not only used in metastatic situations but also more and
      more in adjuvant situations, in other words for patients treated for a localised tumour,
      presenting a risk of relapse. A severe toxic risk cannot be tolerated in these conditions,
      and the doctor should assure the maximum level of safety for his patients. These medicines
      are the cause of 3% of grade IV toxicity from the first or second administration, and for
      0.3% of deaths. To this one can add on a total of 20 to 25% grade III-IV toxic events.

      Anticancer treatment is mostly administered by body size and in the best of cases after a few
      basic biological examinations such as a haemogram and renal status, without taking into
      consideration any individual particularities, whether genetic or epigenetic. Among potential
      toxicity risk factors one can find individual metabolic differences linked to genetic
      modifications of metabolism enzymes as well as differences in the chemical receptors and
      transporters.

      For fluoropyrimidines, a polymorphism was found for the dihydropyrimidine dehydrogenase gene
      (DPD), a major catabolism enzyme. A deficit of this enzyme is a major counter-indication for
      the use of these medicines.

      Early determination of DPD status would allow identification of patients at risk and would
      thus help in subsequent dose adjustment or selection of other treatment modalities.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study stopped due to a death in the arm control
  </why_stopped>
  <start_date type="Actual">June 16, 2008</start_date>
  <completion_date type="Actual">March 4, 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and nature of grade IV toxicity.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>The percentage of severe toxicity (grade IV) will be analyzed in each arm. We expect a reduction of the early, severe, grade IV acute side-effects from 3% to 0.6% in the detected group with adapted doses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of grade III-IV toxic events.</measure>
    <time_frame>Up to 6 months.</time_frame>
    <description>We expect a reduction of the number of grade III-IV toxic events, whenever they occur, from 25% to 5% in the detected group with adapted doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate.</measure>
    <time_frame>up to 6 months.</time_frame>
    <description>The current mortality rate of 3 per thousand patients will be cut to 0 in the detected group with adapted doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical-financial study of pre-therapeutic screening.</measure>
    <time_frame>Up to 6 months.</time_frame>
    <description>We will carry out a comparison of the prevention costs and the costs related to treating patients with toxicity. Direct costs and indirect costs will be taken into account.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1142</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Intravenous 5 Fluorouracile</condition>
  <arm_group>
    <arm_group_label>A : pre-therapeutic screening for DPD deficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : no pretherapeutic research of DPD deficiency</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sample for phenotypic and pharmacogenetic analysis.</intervention_name>
    <description>Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).</description>
    <arm_group_label>A : pre-therapeutic screening for DPD deficiency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sample for phenotypic and pharmacogenetic analysis.</intervention_name>
    <description>Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.</description>
    <arm_group_label>B : no pretherapeutic research of DPD deficiency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  colorectal cancer, histologically confirmed, with all types included (including
             adjuvant cases), requiring treatment with intravenous 5-fluorouracil.

          -  anterior chemotherapy authorised, with the exception of chemotherapy containing a
             derivate of 5-Fluorouracil

          -  Age &gt; or = 18 years

          -  WHO Performance status &lt; or = 2

          -  Haematologic and hepatic parameters : neutrophils &gt; or = 1000 /mm3, platelets &gt; or =
             100000/mm3, Total bilirubin &lt; or = 2 x ULN, AST and ALT &lt; or = 3 x ULN, APL &lt; or = 5 x
             ULN

          -  Complete initial assessment before first treatment administration for imaging and
             pharmacogenetic, within 15 days for biology, and within 7 days for clinical
             examination.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Prior chemotherapy with fluoropyrimidines

          -  Symptomatic or uncontrolled ventral nervous system metastases

          -  Psychiatric Disease disrupting the trial understanding and the enlightened and
             voluntary consent character

          -  Patient who is pregnant or breast feeding

          -  Woman not consenting to use adequate contraceptive precautions during the study

          -  Patient who can not submit itself to the formal follow-up for psychological, social,
             family or geographical reasons

          -  Significant serious pathology or any instable medical condition (cardiac pathology
             uncontrolled, myocardial infarction within 6 months before enrollment, systemic active
             uncontrolled infection)

          -  any investigational agent within 4 weeks before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Capitain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besan√ßon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU C√¥te de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P√¥le Sant√© L√©onard de Vinci</name>
      <address>
        <city>Chambray-les-Tours</city>
        <zip>37175</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Haut Anjou</name>
      <address>
        <city>Chateau-Gontier</city>
        <zip>53204</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Cholet</city>
        <zip>49325</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des C√®dres</name>
      <address>
        <city>Cornebarrieu</city>
        <zip>31700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital Henri Mondor</name>
      <address>
        <city>Cr√©teil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Sarthe et Loir</name>
      <address>
        <city>La Fl√®che</city>
        <zip>72205</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Les oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85929</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Laval</city>
        <zip>53015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>53020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre B√©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saumur</city>
        <zip>49403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Ren√© Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>DihydroPyrimidine Dehydrogenase</keyword>
  <keyword>Lethal toxicity</keyword>
  <keyword>Fluoropyrimidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

